Kornimate/medical-research-clean huggingface dataset:
sib in upper thoracic esophageal squamous cell carcinoma

Conditions: Esophageal Squamous Cell Carcinoma

Summary: this study was designed to predict the toxicity and efficacy of simultaneous integrated boost intensity-modulated chemoradiotherapy in upper thoracic i-iva esophageal squamous cell carcinoma.


Eligibility criteria:
inclusion criteria: 1. histological or cytologic diagnosis of esophageal squamous carcinoma; 2. aged 18-75 years; 3. kps ≥ 70; 4. upper thoracic esophageal squamous carcinoma: the upper margin of the lesion is located between the entrance of esophagus and the inferior edge of the azygos vein; 5. stage i-iva(ajcc 6th,2009); 6. not able to be surgically resection or rejected; 7. not have received any prior anticancer therapy; 8. no serious system dysfunction and immuno-deficiency, adequate organ function including the following: hemoglobin ≥9 g/dl, wbc≥4x109/l, neutrophils (anc )≥1.5x10\^9/l, platelet count ≥100x 10\^9/l, serum creatinine\<1.5 mg/dl,urea nitrogen \<8 mmol/l; 9. no history of malignancy; 10. no perforation of esophagus, no deep ulcer of esophagus; 11. joined the study voluntarily and signed informed consent form. exclusion criteria: 1. pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives; 2. patient who has metastasis such as lung, liver metastasis; 3. other malignant tumors; 4. uncontrolled seizures or psychiatric diseases, loss of control over their own behavior; 5. uncontrollable heart disease, diabetes and hypertension, pulmonary fibrosis, and chest confirmed active pulmonary inflammation require antibiotic treatment, as well as superior vena cava compression syndrome; 6. after surgery, exploratory thoracotomy, radiotherapy, chemotherapy, or targeting therapy; 7. combination of pure red cell anemia or gamma globulin; 8. allergic to any medication component studied.

Keywords: esophageal cancer chemoradiotherapy simultaneous integrated boost intensity
bacteriophages to treat liver disease eliminating harmful bacteria (battle)

Conditions: Alcoholic Hepatitis

Summary: alcoholic hepatitis is a disease with a high mortality rate with few treatment options improving survival. recently certain bacterial strains has been correlated to survival in patients with alcoholic hepatitis. in the battle-trial the investigators will investigate if certain bacteria are correlated to decreased chance of survival in patients with alcoholic hepatitis.

patients with alcoholic hepatitis who are admitted to copenhagen university hospital hvidovre and herlev will be invited to participate. blood and fecal samples following hospital admission will be collected. through one-year follow-up correlation of certain bacteria in fecal samples with survival will be investigated. in particular whether patients with cytolysin producing e. faecalis has a decreased chance of survival compared to patients without this bacteria.

Eligibility criteria:
inclusion criteria: * age ≥ 18 * bilirubin \> 50 micromol/l * history of large alcoholic consumption in period prior to hospital admission (in the last six months) * no bile-duct obstruction (investigated through us, ct og mri) exclusion criteria: * hepatocellulary carcinoma * viral hepatitis * autoimmune hepatitis * portal vein thrombosis * pregnancy * expected survival for less than one year caused by other diseases (based on decision from project responsible doctors

Keywords: gut microbiome
argon plasma coagulation and clip for the prophylaxis of post-polypectomy bleeding after hot snare polypectomy

Conditions: Post-polypectomy Bleeding; Colorectal Polyp

Summary: discuss the efficacy and safety of argon plasma coagulation （apc）in comparison with clip closure for preventing colorectal post-procedure bleeding（ppb） after hot snare polypectomy（hsp）; analyze the risk factors and the cost-effectiveness of bleeding prophylaxis strategies with decision tree analytical method.

this is a multicenter, randomized and controlled study. it aims to discuss the efficacy and safety of argon plasma coagulation（apc）in comparison with clip closure for preventing colorectal post-procedure bleeding（ppb） after hot snare polypectomy（hsp）, and analyze the risk factors and the cost-effectiveness of bleeding prophylaxis strategies with decision tree analytical method. according to the prophylaxis measures, patients enrolled in this study will be randomized into the control group, apc group and clip group. it will collect participants' data of baseline character, postoperative and follow-up. all statistical analyses will be performed by spss 26.0 and tree age pro 2011. based on the previous studies, it is presumed that the rate of ppb for the control group, clip group and apc group is 8%, 2% and 2%. given two-side testing, an alpha of 0.05 and a power of 90%, allowing for a 5% dropout rate, the smallest sample size is 1287.

Eligibility criteria:
inclusion criteria: 1. age\>18 years 2. the diagnosis of colorectal polyps is clear（paris ip or ⅰsp） 3. head diameter≥ 10 mm 4. hsp indications were met and no contraindications were found 5. patients (or the legal representative/guardian) with informed consent exclusion criteria: 1. asa grade ⅲ or above, or end-stage disease of major organs (such as malignancy, heart failure, chronic obstructive pulmonary disease, end-stage renal disease and so on) 2. coagulation dysfunction (inr ≥ 1.5, plt \< 50×10 \^9 / l) 3. use antiplatelet drugs within 7 days before the operation, anticoagulant drugs within 5 days, and/or blood products within 30 days after the operation 4. there were other lesions in the resection site of the included polyps affecting this study, or the intestinal preparation was insufficient 5. incomplete closure of clips (complete closure: spacing between adjacent clips \< 1cm) 6. apc is used for polypectomy or intraoperative hemostasis, rather than preventing ppb 7. surgical treatment, vascular intervention, or blood products were used during the operation 8. use other methods to prevent ppb 9. the bleeding site was not confirmed by endoscopy 10. history of intestinal surgery 11. menstruation or pregnancy 12. not following medical advice 13. participated in other clinical trials and signed its informed consent

Keywords: hot snare polypectomy argon plasma coagulation clip closure
phase i randomized, open-label, parallel-controlled, pharmacokinetic and safety study of br201 injection versus cosentyx in healthy male subjects

Conditions: Psoriasis

Summary: this is a randomized, open-label, controlled phase i study of br201 administered by subcutaneous injection. this study will characterize the pharmacokinetic, safety and immunogenicity of br201 versus cosentyx（secukinumab ） in healthy male subjects after a single dose.


Eligibility criteria:
inclusion criteria: * able to understand and sign informed consent form； * healthy men 18-50 years of age at time of consent； * body weight of ≥50 kg and ≤ 80 kg and bmi ≥19 and ≤ 26 kg/m2. exclusion criteria: * clinical laboratory examination results are abnormal and with clinical significance, or other clinical findings indicate diseases (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, tumor, pulmonary, immune, mental or cardiovascular and cerebrovascular diseases) with clinical significance; * use of il-17 or other monoclonal antibodies in the last 6 months; * positive for anti-il-17 antibodies at screening; * evidence of tuberculosis infection; * with active infection at screening or have been hospitalized for a serious infection during the 8 months prior to screening or use of antibiotics within 2 weeks of enrollment; * anti-il-17 antibody active ingredient, excipients or latex allergy; * with severe bleeding factors that affect venous blood collection or unwilling to undergo venipuncture; * use drug treatment (including prescription drugs, over-the-counter drugs, health product etc.) within 14 days before screening; * surgery within 2 months prior to screening; or plan to have surgery during the study period;. * have received live vaccines within 6 months prior to screening, or have used any vaccines within 4 weeks prior to screening, or plan to be vaccinated during the trial.; * history of malignant neoplasms； * hepatitis b and/or hepatitis c; or hiv antigen/antibody positive; or treponema pallidum antibody positive; . * blood donation or massive blood loss (\> 400 ml) within 3 months or blood loss (\> 200 ml) within 1 month before signing the informed consent; or plan to donate blood during the trial; * have a history of drug or substance abuse before screening; or positive drug abuse test results on the day of check-in; * acute disease occurred or with concomitant medication from the screening to use of the study drug.; * have pregnancy plan or sperm donation plan during the whole trial period and within 6 months after the completion of the study; * other conditions considered inappropriate to be included in this study.
comparison of seeox and sox regimens in stage ⅲb/ⅲc gastric cancer patients

Conditions: Stomach Neoplasms; Gastric Cancer

Summary: chemotherapy is an important therapeutic method for patients with advanced gastric cancer. however, there is currently no established standard chemotherapeutic regimen in the preoperative or neoadjuvant treatment setting. the aim of our study was to compare the efficacy and toxicity between seeox and sox regimens. the investigators estimate that combined intravenous and intra-arterial intensified seeox preoperative chemotherapy may be a safe and promising regimen for locally advanced or initially unresectable gastric cancer patients.

gastric cancer patients who will receive neoadjuvant chemotherapy would be included in this study. they would receive combined intravenous and intra-arterial intensified seeox neoadjuvant chemotherapy or sox regimen at random. the efficacy and toxicity of these two regimens would be compared.

Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group(ecog) score 0-2 * ambulatory males or females, aged 30-70 years. * unresectable gastric cancer (tumors with bulky nodal metastases surrounding the celiac artery and its branches or invasion of adjacent structures such as pancreas, omentum, esophagus, and aorta were considered unresectable) * life expectancy more than 3 months * give written informed consent, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice. * normal hepatic, renal, and bone marrow function (gpt\ 4000/dl, tbil\<1.5mg/dl, cr\<1.5 fold of upper limit value) exclusion criteria: * patients can not bear surgical procedure. * pregnant or lactating women. * previous cytotoxic chemotherapy, radiotherapy or immunotherapy. * history of another malignancy within the last five years. * history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake. * clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery disease, new york heart association (nyha) grade ii or greater congestive heart failure or serious cardiac arrhythmia requiring medication or myocardial infarction within the last 12 months. * organ allografts requiring immunosuppressive therapy. * serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease. * moderate or severe renal impairment: serum creatinine \> 1.5 x upper limit of normal (uln). * hypersensitivity to any drug of the study regimen. * with abdominal cavity implantation metastasis or distant metastasis. * unwilling or unable to comply with the protocol for the duration of the study.

Keywords: gastric cancer neoadjuvant chemotherapy efficacy safety
accent mri pacemaker and tendril mri lead new technology assessment

Conditions: Bradycardia

Summary: the intent of this study is to evaluate the performance of the implanted accent mri tm system in a clinical setting and optionally in the mri environment. this system includes the st. jude medical tendril mri™ lead and sjm accent mritm dr pacemaker. also the mri activator™ will be evaluated in this study. the mri activator is a handheld device that allows the user to enable and disable mri settings as well as check the status of mri settings in the pacemaker. the patient population under study includes patients with a standard bradycardia pacing indication.


Eligibility criteria:
inclusion criteria: * approved class i or class ii indication per esc guidelines for implantation of a dual chamber pacemaker or single chamber pacemaker. * receiving a new accent mritm pacemaker and tendril mri™ lead (either initial implant or complete system change out with no abandoned devices). * ability to provide informed consent for study participation. * is willing and able to comply with the prescribed follow-up tests and schedule of evaluations. exclusion criteria: * have an existing pacemaker or icd (abandoned devices and/or leads are not allowed. a new pacemaker and lead or complete system change out is required for enrollment). * have an existing active/inactive implanted medical device (e. g., neurostimulator, infusion pump, etc.). * have a non-mri compatible device or material implant (e.g., intracranial aneurysm clip, non-mri compatible devices or material, metals or alloys, etc.). * have a lead extender or adaptor. * have a mechanical, prosthetic or bioprosthetic tricuspid heart valve. * have an abdominal diameter (approximately \> 60cm) which results in contact with the magnet façade. * are currently participating in a study that includes an active treatment arm. * are pregnant or planning to become pregnant during the duration of the study. * have a life expectancy of less than 6 months due to any condition. * are less than 18 years of age. * are unable to comply with the follow up schedule.
enrichment of human milk with human and bovine milk-based fortifiers for very preterm infants: a meta-analysis

Conditions: Human Milk Fortification; Very Low Birth Weight Baby; Human Milk Nutrition; Human Milk Feeding; Necrotizing Enterocolitis (NEC); Late Onset Neonatal Sepsis; Growth; Feeding Intolerance in Preterm; Infant Mortality

Summary: research has shown that provision of mother's milk is the optimal way to feed very low birthweight (vlbw) infants. many infants will require a supplement to mother's milk, pasteurized donor human milk (pdhm) compared to preterm formula is the most appropriate supplement as it has been shown to reduce the risk of necrotizing enterocolitis (nec). most available evidence suggests neither mother's milk nor pdhm will meet the elevated nutritional requirements of vlbw infants without multi-nutrient fortification. globally, the current standard of care is to use bovine protein-based nutrient fortifiers to meet these elevated nutrient requirements. given the known benefits of mother's milk, the reduction in the risk of nec with use of pdhm as a supplement, and the availability of human milk-based multi-nutrient fortifiers (hmbf), there has been considerable interest in the efficacy of hmbf over the less costly bovine milk-based fortifiers (bmbf). this study is an analysis of individual participant data merged from randomized control trials that examined the efficacy of hmbf compared to bmbf during hospitalization, on the risk of death and severe morbidity or major feeding interruption. participants of the trials included in the analyses were fed exclusively with human milk or a supplement of pasteurized donor human milk (pdhm). only two rcts met this criteria -optimom and the n-forte trial. in both studies the intervention aligned to commence upon randomization into the hmbf or bmbf groups. the difference between the optimom and n-forte feeding protocols was that the later allowed for individualized fortification based on milk analysis whereas optimom used standard fortification, predominant in canada and globally. for optimom, the feeding intervention continued until infants were 84 days of age, discharge, or when the infant consumed ≥2 complete oral feeds daily. for n-forte trial, the feeding intervention ended when babies reached 34 weeks (zero days). both studies followed participants and continued data collection if transferred to a level ii nicu for convalescence (optimom) or home care service followed closely by nicu nurses (n-forte) until discharge.


Eligibility criteria:
inclusion criteria: • infant is a participant of the optimom or the n-forte trial.

Keywords: bovine based vs human milk based fortifiers rcts meta-analysis human milk fortifiers (hmf)
long-term safety study of kw-6500 in patients with parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of this study is to evaluate the safety and efficacy of kw-6500 when administered as long-term subcutaneous self-injections in parkinson's disease patients with motor response complications on levodopa therapy.


Eligibility criteria:
inclusion criteria: * patients who have given written informed consent * patients who have parkinson's disease * patients who have been on a stable regimen of levodopa plus at least one other antiparkinsonian agent and who have off state * patients who meet stage 4 or 5 while in the off state and stage 0 to 3 while in the on state on the modified hoehn and yahr scale * patients who have experienced a 30% or more improvement in updrs partⅲ score when tested for responsiveness to levodopa during the baseline period * patients who have at least one off state per day * patients who can understand the expression of off state, on state, and dyskinesia * patients or their families have a desire for self-injection of kw-6500 exclusion criteria: * patients with an illness of the cardiac, hematologic, hepatic, renal, pancreatic, metabolic, respiratory, gastrointestinal, endocrinologic, or neurologic system (excluding parkinson's disease) * patients with orthostatic hypotension * patients with a history of intolerance to morphine or its derivatives, sulfur, sulfur-containing pharmaceutical products, or sulfite * patients with a history of malignant syndrome * patients with a diagnosis of cancer or evidence of continued disease * patients who do not test negative in the direct coombs' test * pregnant or lactating women, women who are planning to have children, women who test positive in the pregnancy test, or women who cannot adhere to a reliable method of contraception * patients who have received mao inhibitors except selegiline * patients with a history of mental disease (excluding psychiatric symptoms associated with parkinson's disease) * patients with a mini-mental state examination (mmse) score of 23 or less * patients who are taking antipsychotics or central dopamine antagonists (excluding domperidone) * patients who are receiving methyldopa or 5-ht3 receptor antagonists * patients who are receiving reserpine or papaverine * patients who have had a neurosurgical operation for parkinson's disease * patients who have had transcranial magnetic stimulation * patients with a history of drug or alcohol abuse or dependence
physical, psychological and socioeconomic effects of childhood onset diabetes in sweden

Conditions: Type 1 Diabetes Mellitus (T1DM); End-Stage Renal Disease

Summary: the researchers study time trends of childhood-onset type 1 diabetes and its most serious complication, end-stage renal disease. they further analyse physical, psychological and socio-economic long-term effects on patients and families to identify potentially preventive factors in a population perspective. the researchers investigate the economic burden of disease and study and improve statistical methods for case-control data. the projects use a longitudinal nationwide database involving about 23 000 childhood-onset diabetes cases with maximum follow-up of 48 years and for each case 4 matched controls. the swedish childhood diabetes register is linked to a number of official, swedish registers: the renal register, the cause of death register, the national patient register, the prescribed drugs register, the cancer register and the integrated database for labour market research. the researchers use gam modelling for time trend analyses, standard case-control/cohort analyses, cox regression for life table analyses, linear fixed effect probability for career development and propensity score models for confounding. the project group is multidisciplinary and involves experts in paediatrics, nephrology, epidemiology, health economics and statistics. this unique database and team continues to yield population-based new knowledge on the consequences of this increasingly common chronic childhood-onset disease.


Eligibility criteria:
inclusion criteria: * two prescriptions of insulin in the prescribed drug register. * age below 15 years of age. controls are of the same age and born in the same municipality as the cases. exclusion criteria: * no

Keywords: type 1 diabetes childhood-onset risk factors complications socioeconomic conditions
detection of early esophageal squamous neoplasia

Conditions: Esophageal Squamous Intraepithelial Neoplasia

Summary: the aim of the present study： 1. to investigate the diagnosing value of pcle for early esophageal squamous neoplasia. 2. to assess the detection rate of early esophageal squamous neoplasia by virtual chromoendoscopy

probe-based confocal laser endomicroscopy (pcle; cellvizio, mauna kea technologies, paris, france) is a newly developed endoscopic device and has shown its value for diagnosing barrett's esophagus, colonal polyps and etc. however, none research has focus on early esophageal squamous neoplasia until now. previous diagnosis of early esophageal neoplasia is based on the lugol staining which is time wasting and have many adverse events.other researches have suggested virtual chromoendoscopys are beneficial for screening esophageal tumors. therefore, the aim of the present study is 1.to investigate the diagnosing value of pcle for early esophageal squamous neoplasia according to the surface maturation scoring(sms) diagnostic criteria and 2. to assess the detection rate of early esophageal squamous neoplasia by virtual chromoendoscopy(i-scan).

Eligibility criteria:
inclusion criteria: * patients aged between 50 and 80 years old * patients undergo screening endoscopy or histologically verified esophageal squamous intraepithelial neoplasia before. exclusion criteria: * advanced esophageal, gastric or duodenal cancer * history of upper gi tract surgery * coagulopathy or acute gi bleeding * pregnant or breast-feeding (for females) * impaired renal function * allergy to fluorescein sodium * inability to provide informed consent.

Keywords: esophageal squamous intraepithelial neoplasia surface maturation scoring probe-based confocal laser endomicroscopy virtual chromoendoscopy
comparison of quality of recovery (qor)-15 scores between propofol and remimazolam anesthesia

Conditions: Patients Undergoing Thyroid Surgery for Neoplasm

Summary: remimazolam is a ultra-short-acting benzodiazepine that is rapidly metabolized in the body by tissue esterase and not accumulates in the body for long periods of infusion. in addition, similar to other benzodiazepines, it is possible to reverse the sedation and anesthetic effects through flumazenil. it has no injection pain and infusion syndrome compared with propofol. there is no study to investigate overall postoperative functional recovery via qor-15 in patients receiving tiva using remimazolam. the purpose of this study is to determine whether there is any difference in the quality of postoperative recovery between propofol-based and remimazolam-based total intravenous anesthesia in female patients undergoing thyroidectomy. the qor-15 questionnaire score, pain, nausea/vomiting, and the frequency of complications are evaluated and compared between the two groups.


Eligibility criteria:
inclusion criteria: •20≤age≤65 female open thyroidectomy asa-ps i-iii exclusion criteria: * allergic history of any study drug * taking any sedative, opioid, or sleep aid drugs * psychiatric or neurological disorder * bmi\>30 kg/m2 * pregnancy * vulnerable patients